Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention
2019 · JAMA · 588 citations
https://doi.org/10.1001/jama.2019.8146
T
Taek Kyu Park
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
315
Papers
6.8K
Citations
42
h-index
122
i10-index
Taek Kyu Park is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Coronary Interventions and Diagnostics & Cardiac Imaging and Diagnostics & Acute Myocardial Infarction Research. The author has an h-index of 42, co-authored 268 publications.
ORCID: 0000-0003-1440-3583Papers by this author
works6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
2018 · The Lancet · 352 citations
https://doi.org/10.1016/s0140-6736(18)30493-8
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
2018 · The Lancet · 352 citations
https://doi.org/10.1016/s0140-6736(18)30493-8
Clinical impact of intra-aortic balloon pump during extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock
2014 · BMC Anesthesiology · 74 citations
https://doi.org/10.1186/1471-2253-14-27
Physiological Distribution and Local Severity of Coronary Artery Disease and Outcomes After Percutaneous Coronary Intervention
2021 · JACC: Cardiovascular Interventions · 65 citations
https://doi.org/10.1016/j.jcin.2021.06.013
Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial
2025 · The Lancet · 54 citations
https://doi.org/10.1016/s0140-6736(25)00449-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat